首页> 美国卫生研究院文献>Clinical and Experimental Gastroenterology >Systematic review of randomized controlled trials of probiotics prebiotics and synbiotics in inflammatory bowel disease
【2h】

Systematic review of randomized controlled trials of probiotics prebiotics and synbiotics in inflammatory bowel disease

机译:益生菌益生元和合生元治疗炎症性肠病的随机对照试验的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundProbiotics are microorganisms that are ingested either in combination or as a single organism in an effort to normalize intestinal microbiota and potentially improve intestinal barrier function. Recent evidence has suggested that inflammatory bowel disease (IBD) may result from an inappropriate immunologic response to intestinal bacteria and a disruption in the balance of the gastrointestinal microbiota in genetically susceptible individuals. Prebiotics, synbiotics, and probiotics have all been studied with growing interest as adjuncts to standard therapies for IBD. In general, probiotics have been shown to be well-tolerated with few side effects, making them a potential attractive treatment option in the management of IBD.
机译:背景益生菌是组合摄入或作为单一生物体摄入的微生物,旨在使肠道菌群正常化并可能改善肠道屏障功能。最近的证据表明,炎症性肠病(IBD)可能是由于对肠道细菌的不适当免疫反应以及遗传易感个体中胃肠道菌群平衡的破坏所致。益生元,合生元和益生菌都已作为IBD标准疗法的辅助手段而受到越来越多的关注。一般而言,益生菌已被证明具有良好的耐受性,几乎没有副作用,这使其成为治疗IBD的潜在有吸引力的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号